Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arne C. Rufer is active.

Publication


Featured researches published by Arne C. Rufer.


Proceedings of the National Academy of Sciences of the United States of America | 2011

Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose

Claudia Ferrara; Sandra Grau; Christiane Jäger; Peter Sondermann; Peter Brünker; Inja Waldhauer; Michael Hennig; Armin Ruf; Arne C. Rufer; Martine Stihle; Pablo Umana; Jörg Benz

Antibody-mediated cellular cytotoxicity (ADCC), a key immune effector mechanism, relies on the binding of antigen–antibody complexes to Fcγ receptors expressed on immune cells. Antibodies lacking core fucosylation show a large increase in affinity for FcγRIIIa leading to an improved receptor-mediated effector function. Although afucosylated IgGs exist naturally, a next generation of recombinant therapeutic, glycoenginereed antibodies is currently being developed to exploit this finding. In this study, the crystal structures of a glycosylated Fcγ receptor complexed with either afucosylated or fucosylated Fc were determined allowing a detailed, molecular understanding of the regulatory role of Fc-oligosaccharide core fucosylation in improving ADCC. The structures reveal a unique type of interface consisting of carbohydrate–carbohydrate interactions between glycans of the receptor and the afucosylated Fc. In contrast, in the complex structure with fucosylated Fc, these contacts are weakened or nonexistent, explaining the decreased affinity for the receptor. These findings allow us to understand the higher efficacy of therapeutic antibodies lacking the core fucose and also suggest a unique mechanism by which the immune system can regulate antibody-mediated effector functions.


Journal of Biological Chemistry | 2008

Structural Properties of AMP-activated Protein Kinase DIMERIZATION, MOLECULAR SHAPE, AND CHANGES UPON LIGAND BINDING

Uwe Riek; Roland W. Scholz; Peter V. Konarev; Arne C. Rufer; Marianne Suter; Alexis Nazabal; Philippe Ringler; Mohamed Chami; Shirley A. Müller; Dietbert Neumann; Michael Forstner; Michael Hennig; Renato Zenobi; Andreas Engel; Dimitri I. Svergun; Uwe Schlattner; Theo Wallimann

Heterotrimeric AMP-activated protein kinase (AMPK) is crucial for energy homeostasis of eukaryotic cells and organisms. Here we report on (i) bacterial expression of untagged mammalian AMPK isoform combinations, all containing γ1, (ii) an automated four-dimensional purification protocol, and (iii) biophysical characterization of AMPK heterotrimers by small angle x-ray scattering in solution (SAXS), transmission and scanning transmission electron microscopy (TEM, STEM), and mass spectrometry (MS). AMPK in solution at low concentrations (∼1 mg/ml) largely consisted of individual heterotrimers in TEM analysis, revealed a precise 1:1:1 stoichiometry of the three subunits in MS, and behaved as an ideal solution in SAXS. At higher AMPK concentrations, SAXS revealed concentration-dependent, reversible dimerization of AMPK heterotrimers and formation of higher oligomers, also confirmed by STEM mass measurements. Single particle reconstruction and averaging by SAXS and TEM, respectively, revealed similar elongated, flat AMPK particles with protrusions and an indentation. In the lower AMPK concentration range, addition of AMP resulted in a significant decrease of the radius of gyration by ∼5% in SAXS, which indicates a conformational switch in AMPK induced by ligand binding. We propose a structural model involving a ligand-induced relative movement of the kinase domain resulting in a more compact heterotrimer and a conformational change in the kinase domain that protects AMPK from dephosphorylation of Thr172, thus positively affecting AMPK activity.


Pharmaceutical Research | 2012

Structure and function of purified monoclonal antibody dimers induced by different stress conditions

Rajsekhar Paul; Alexandra Graff-Meyer; Henning Stahlberg; Matthias E. Lauer; Arne C. Rufer; Hermann Beck; Alexandre Briguet; Volker Schnaible; Thomas Buckel; Sabine Boeckle

ABSTRACTPurposeTo investigate structure and function of different monoclonal antibody (MAb) dimers.MethodsMAb dimers were induced by process-related, low pH and UV light stress. Dimers were isolated and purified by chromatography and extensively characterized by biochemical, structural and functional methods.ResultsHighly purified dimer forms were obtained which enabled detailed characterization. Dimers induced by process stress were associated by a single non-covalent interaction site between two Fab domains in a characteristic “bone-like” structure observed in Transmission Electron Microscopy (TEM). These dimers showed reduced potency and antigen binding affinity. Low pH stress generated more stable but also non-covalently associated dimers without chemical alterations in a typical “closed” conformation according to TEM. These dimer species were more compact and more hydrophobic as dimers induced by process stress. They showed bioactivity and antigen binding affinity similar to the native monomer. Light-induced dimers, exhibiting various different conformations, were the most stable dimers with various chemical modifications leading to a broad range in size, charge and hydrophobicity. These dimers fully lost bioactivity and antigen binding affinity.ConclusionThe use of highly purified MAb dimers and a panel of characterizations methods enabled to obtain a clear picture about molecular architecture and function of dimers.


Biochimica et Biophysica Acta | 2015

Real-time monitoring of binding events on a thermostabilized human A2A receptor embedded in a lipid bilayer by surface plasmon resonance

Nicolas Bocquet; Josiane Kohler; Melanie N. Hug; Eric Kusznir; Arne C. Rufer; Roger J. P. Dawson; Michael Hennig; Armin Ruf; Walter Huber; Sylwia Huber

Membrane proteins (MPs) are prevalent drug discovery targets involved in many cell processes. Despite their high potential as drug targets, the study of MPs has been hindered by limitations in expression, purification and stabilization in order to acquire thermodynamic and kinetic parameters of small molecules binding. These bottlenecks are grounded on the mandatory use of detergents to isolate and extract MPs from the cell plasma membrane and the coexistence of multiple conformations, which reflects biochemical versatility and intrinsic instability of MPs. In this work ,we set out to define a new strategy to enable surface plasmon resonance (SPR) measurements on a thermostabilized and truncated version of the human adenosine (A2A) G-protein-coupled receptor (GPCR) inserted in a lipid bilayer nanodisc in a label- and detergent-free manner by using a combination of affinity tags and GFP-based fluorescence techniques. We were able to detect and characterize small molecules binding kinetics on a GPCR fully embedded in a lipid environment. By providing a comparison between different binding assays in membranes, nanodiscs and detergent micelles, we show that nanodiscs can be used for small molecule binding studies by SPR to enhance the MP stability and to trigger a more native-like behaviour when compared to kinetics on A2A receptors isolated in detergent. This work provides thus a new methodology in drug discovery to characterize the binding kinetics of small molecule ligands for MPs targets in a lipid environment.


mAbs | 2012

Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain

Daniel Schlatter; Simon Brack; David W. Banner; Sarah Batey; Jörg Benz; Julian Bertschinger; Walter Huber; Catherine Joseph; Arne C. Rufer; Anita van der Klooster; Martin Weber; Dragan Grabulovski; Michael Hennig

The serine protease chymase (EC = 3.4.21.39) is expressed in the secretory granules of mast cells, which are important in allergic reactions. Fynomers, which are binding proteins derived from the Fyn SH3 domain, were generated against human chymase to produce binding partners to facilitate crystallization, structure determination and structure-based drug discovery, and to provide inhibitors of chymase for therapeutic applications. The best Fynomer was found to bind chymase with a KD of 0.9 nM and koff of 6.6x10−4 s−1, and to selectively inhibit chymase activity with an IC50 value of 2 nM. Three different Fynomers were co-crystallized with chymase in 6 different crystal forms overall, with diffraction quality in the range of 2.25 to 1.4 Å resolution, which is suitable for drug design efforts. The X-ray structures show that all Fynomers bind to the active site of chymase. The conserved residues Arg15-Trp16-Thr17 in the RT-loop of the chymase binding Fynomers provide a tight interaction, with Trp16 pointing deep into the S1 pocket of chymase. These results confirm the suitability of Fynomers as research tools to facilitate protein crystallization, as well as for the development of assays to investigate the biological mechanism of targets. Finally, their highly specific inhibitory activity and favorable molecular properties support the use of Fynomers as potential therapeutic agents.


Cellular and Molecular Life Sciences | 2009

Structural insight into function and regulation of carnitine palmitoyltransferase

Arne C. Rufer; Ralf Thoma; Michael Hennig

The control of fatty acid translocation across the mitochondrial membrane is mediated by the carnitine palmitoyltransferase (CPT) system. Modulation of its functionality has simultaneous effects on fatty acid and glucose metabolism. This encourages use of the CPT system as drug target for reduction of gluconeogenesis and restoration of lipid homeostasis, which are beneficial in the treatment of type 2 diabetes mellitus and obesity. Recently, crystal structures of CPT-2 were determined in uninhibited forms and in complexes with inhibitory substrate-analogs with anti-diabetic properties in animal models and in clinical studies. The CPT-2 crystal structures have advanced understanding of CPT structure–function relationships and will facilitate discovery of novel inhibitors by structure-based drug design. However, a number of unresolved questions regarding the biochemistry and pharmacology of CPT enzymes remain and are addressed in this review.


Acta Crystallographica Section D-biological Crystallography | 2013

Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones

David W. Banner; Bernard Gsell; Jörg Benz; Julian Bertschinger; Dominique Burger; Simon Brack; Simon Cuppuleri; Maja Debulpaep; Alain Gast; Dragan Grabulovski; Michael Hennig; Hans Hilpert; Walter Huber; Andreas Kuglstatter; Eric Kusznir; Toon Laeremans; Hugues Matile; Christian Miscenic; Arne C. Rufer; Daniel Schlatter; Jan Steyaert; Martine Stihle; Ralf Thoma; Martin Weber; Armin Ruf

The aspartic protease BACE2 is responsible for the shedding of the transmembrane protein Tmem27 from the surface of pancreatic β-cells, which leads to inactivation of the β-cell proliferating activity of Tmem27. This role of BACE2 in the control of β-cell maintenance suggests BACE2 as a drug target for diabetes. Inhibition of BACE2 has recently been shown to lead to improved control of glucose homeostasis and to increased insulin levels in insulin-resistant mice. BACE2 has 52% sequence identity to the well studied Alzheimers disease target enzyme β-secretase (BACE1). High-resolution BACE2 structures would contribute significantly to the investigation of this enzyme as either a drug target or anti-target. Surface mutagenesis, BACE2-binding antibody Fab fragments, single-domain camelid antibody VHH fragments (Xaperones) and Fyn-kinase-derived SH3 domains (Fynomers) were used as crystallization helpers to obtain the first high-resolution structures of BACE2. Eight crystal structures in six different packing environments define an ensemble of low-energy conformations available to the enzyme. Here, the different strategies used for raising and selecting BACE2 binders for cocrystallization are described and the crystallization success, crystal quality and the time and resources needed to obtain suitable crystals are compared.


FEBS Open Bio | 2013

Isothermal titration calorimetry with micelles: Thermodynamics of inhibitor binding to carnitine palmitoyltransferase 2 membrane protein.

Samantha Perspicace; Arne C. Rufer; Ralf Thoma; Francis Mueller; Michael Hennig; Simona M. Ceccarelli; Tanja Schulz-Gasch; Joachim Seelig

Carnitine palmitoyl transferase 2 (CPT‐2) is a key enzyme in the mitochondrial fatty acid metabolism. The active site is comprised of a Y‐shaped tunnel with distinct binding sites for the substrate acylcarnitine and the cofactor CoA. We investigated the thermodynamics of binding of four inhibitors directed against either the CoA or the acylcarnitine binding sites using isothermal titration calorimetry (ITC). CPT‐2 is a monotopic membrane protein and was solubilized by β‐octylglucoside (β‐OG) above its critical micellar concentration (CMC) to perform inhibitor titrations in solutions containing detergent micelles. The CMC of β‐OG in the presence of inhibitors was measured with ITC and small variations were observed. The inhibitors bound to rat CPT‐2 (rCPT‐2) with 1:1 stoichiometry and the dissociation constants were in the range of K D = 2–20 μM. New X‐ray structures and docking models of rCPT‐2 in complex with inhibitors enable an analysis of the thermodynamic data in the context of the interaction observed for the individual binding sites of the ligands. For all ligands the binding enthalpy was exothermic, and enthalpy as well as entropy contributed to the binding reaction, with the exception of ST1326 for which binding was solely enthalpy‐driven. The substrate analog ST1326 binds to the acylcarnitine binding site and a heat capacity change close to zero suggests a balance of electrostatic and hydrophobic interactions. An excellent correlation of the thermodynamic (ITC) and structural (X‐ray crystallography, models) data was observed suggesting that ITC measurements provide valuable information for optimizing inhibitor binding in drug discovery.


FEBS Letters | 2007

Carnitine palmitoyltransferase 2: analysis of membrane association and complex structure with a substrate analog.

Arne C. Rufer; Jörg Benz; Odile Chomienne; Ralf Thoma; Michael Hennig

The mitochondrial membrane‐associated carnitine palmitoyltransferase system is a validated target for the treatment of type 2 diabetes mellitus. To further facilitate structure‐based drug discovery, we determined the crystal structure of rat CPT‐2 (rCPT‐2) in complex with the substrate analogue palmitoyl‐aminocarnitine at 1.8 Å resolution. Biochemical analyses revealed a strong effect of this compound on rCPT‐2 activity and stability. Using a computational approach we examined the membrane association of rCPT‐2. The protein interacts with the membrane as a functional monomer and the calculations confirm the presence of a membrane association domain that consists of layers of hydrophobic and positively charged residues.


Acta Crystallographica Section F-structural Biology and Crystallization Communications | 2005

X-ray structure of glutathione S-transferase from Schistosoma japonicum in a new crystal form reveals flexibility of the substrate-binding site

Arne C. Rufer; Lars Thiebach; Kristin Baer; Helmut W. Klein; Michael Hennig

The crystal structure of the 26 kDa glutathione S-transferase from Schistosoma japonicum (SjGST) was determined at 3 A resolution in the new space group P2(1)2(1)2(1). The structure of orthorhombic SjGST reveals unique features of the ligand-binding site and dimer interface when compared with previously reported structures. SjGST is recognized as the major detoxification enzyme of S. japonicum, a pathogenic helminth causing schistosomiasis. As resistance against the established inhibitor of SjGST, praziquantel, has been reported these results might prove to be valuable for the development of novel drugs.

Collaboration


Dive into the Arne C. Rufer's collaboration.

Top Co-Authors

Avatar

Michael Hennig

European Bioinformatics Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge